NEW YORK (GenomeWeb) — Co-Diagnostics announced today that it has signed definitive agreements to sell $5.5 million in common stock to institutional investors through a registered direct offering.
According to Co-Diagnostics, the agreements call for the sale of roughly 3.9 million shares at $1.40 per share. The offering is expected to close on Monday. HC Wainwright is the exclusive placement agent for the offering.